keyword
MENU ▼
Read by QxMD icon Read
search

Medullary thyroid cancer

keyword
https://www.readbyqxmd.com/read/28635560/sorafenib-in-japanese-patients-with-locally-advanced-or-metastatic-medullary-thyroid-carcinoma-and-anaplastic-thyroid-carcinoma
#1
Yasuhiro Ito, Naoyoshi Onoda, Ken-Ichi Ito, Iwao Sugitani, Shunji Takahashi, Iku Yamaguchi, Koki Kabu, Katsuya Tsukada
BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan even though vandetanib for MTC, and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). We conducted an uncontrolled, open-label, multicenter, single-arm, phase 2 clinical study to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC...
June 21, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28634649/assessment-of-cabozantinib-treatment-on-qt-interval-in-a-phase-3-study-in-medullary-thyroid-cancer-evaluation-of-indirect-qt-effects-mediated-through-treatment-induced-changes-in-serum-electrolytes
#2
Dale R Miles, Steven A Lacy, David R Wada, Steve Milwee, Yifah Yaron, Linh T Nguyen
PURPOSE: This study evaluated factors impacting QTc interval in a phase 3 trial of cabozantinib in progressive, metastatic, medullary thyroid cancer (MTC). METHODS: Electrocardiogram (12-lead ECG) measurements were obtained at screening, and at pre-dose, and 2, 4, and 6 h post-dose on Days 1 and 29 in a phase 3 study in patients with MTC treated with cabozantinib (140 mg/day). Central tendency analyses were conducted on baseline-corrected QTc values. Linear and nonlinear mixed-effects models were used to evaluate potential factors affecting the QTc interval, including serum electrolytes, patient demographics, and cabozantinib concentration...
June 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28633552/cabozantinib-for-the-treatment-of-kidney-cancer
#3
Ahmed Abdelaziz, Ulka Vaishampayan
Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. Areas Covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28621690/ratio-of-positive-lymph-nodes-the-prognostic-value-in-stage-iv-thyroid-cancer
#4
Tingyin Jiang, Chunling Huang, Yuan Xu, Yingrui Su, Guanjie Zhang, Long Xie, Liqun Huang, Shuchun You, Jinshun Zha
To assess the prognostic value of lymph node ratio (LNR) in patients with stage IV thyroid cancer based on the Surveillance, Epidemiology, and End Results (SEER) database. A total of 4,940 eligible patients were included for the analysis. Kaplan-Meier survival analysis and Cox proportional hazard regression were used to reveal the effect of LNR on overall survival (OS) and disease specific survival (DSS). The optimal cut-off value of LNR for predicting OS and DSS was determined by the time-dependent Receiver Operating Characteristic analysis...
June 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28614009/the-combined-use-of-calcitonin-doubling-time-and-18-f-fdg-pet-ct-improves-prognostic-values-in-medullary-thyroid-carcinoma-the-clinical-utility-of-18-f-fdg-pet-ct
#5
Ji H Yang, Cléber P Camacho, Susan C Lindsey, Flavia O F Valente, Danielle M Andreoni, Lilian Y Yamaga, Jairo Wagner, Rosa Paula M Biscolla, Rui M B Maciel
OBJECTIVE: Calcitonin and carcinoembryonic antigen (CEA) doubling times are established prognostic markers in medullary thyroid cancer (MTC). On the other hand, positron emission tomography with fluorine-18 fluorodeoxyglucose ((18)F-FDG PET/CT) shows an increased rate of detection with high blood tumor marker levels in several cancers. This study aims to analyze the ability of (18)F-FDG PET/CT to determine prognosis in the followup of patients with MTC. METHODS: Medical records of 17 patients with MTC who underwent (18)F-FDG PET/CT were analyzed retrospectively...
June 14, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28610401/oncogenesis-of-thyroid-cancer
#6
Enas Younis
Thyroid neoplasms encompass a variety of lesions that range from benign adenomas to malignancies. These latter can be well-differentiated, poorly differentiated or undifferentiated (anaplastic) carcinomas. More than 95% of thyroid cancers are derived from thyroid follicular cells, while 2-3% (medullary thyroid cancers, MTC) originate from calcitonin producing C-cells. Over the last decade, investigators have developed a clearer understanding of genetic alterations underlying thyroid carcinogenesis. A number of point mutations and translocations are involved, not only in its tumorigenesis, but also as have potential use as diagnostic and prognostic indicators and therapeutic targets...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28609830/medullary-thyroid-carcinoma-in-men2a-ata-moderate-or-high-risk-ret-mutations-do-not-predict-disease-aggressiveness
#7
Rachel K Voss, Lei Feng, Jeffrey E Lee, Nancy D Perrier, Paul H Graham, Samual M Hyde, Frances Nieves-Munoz, Maria E Cabanillas, Steven G Waguespack, Gilbert J. Cote, Robert F Gagel, Elizabeth G Grubbs
Context: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations. Objective: To determine if high-risk RET mutations are more aggressive Design: Retrospective cohort study utilizing institutional MEN2 registry Setting: A tertiary cancer care center Patients: Those with MTC and moderate- or high-risk germline RET mutation...
May 9, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28605116/phaeochromocytoma-in-multiple-endocrine-neoplasia-type-2-ret-codon-specific-penetrance-and-changes-in-management-during-the-last-four-decades
#8
L Mucha, G Leidig-Bruckner, K Frank-Raue, Th Bruckner, M Kroiss, F Raue
OBJECTIVES: We describe phaeochromocytoma penetrance in multiple endocrine neoplasia type 2 (MEN2) according to RET protooncogene-specific mutations, and report changes in phaeochromocytoma diagnosis and management from 1968 to 2015. DESIGN: This retrospective chart review included 309 MEN2 patients from one specialised ambulatory care centre. Phaeochromocytoma patients were categorised by diagnosis date: early, 1968-1996, n = 40; and recent, 1997-2015, n = 45. RESULTS: Phaeochromocytoma was diagnosed in 85/309 patients with RET mutations in the following exons (phaeos/all carriers, %): exon 11 (56/120, 46·6%); exon 16 (7/17, 41·2%), exon 10 (14/47, 29·8%), and exon 13-15 (2/116, 1·7%)...
June 12, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28602103/advances-in-small-molecule-therapy-for-treating-metastatic-thyroid-cancer
#9
Jolanta Krajewska, Tomasz Gawlik, Barbara Jarzab
Multi kinase inhibitors (MKIs) are new drugs, which show activity against receptors of different growth factors leading to the inhibition of tumor cells growth and proliferation. This review summarizes a 10-year experience with the use of MKIs in thyroid cancer (TC). It focuses not only on sorafenib, lenvatinib, vandetanib and cabozantinib, already approved in TC, but also presents an overview of the results of different trials with distinct MKIs so far carried out in TC. Areas covered: published results of phase I, II and III studies and other reports evaluated the efficacy of different targeted drugs in TC...
June 12, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28591772/biological-evaluation-of-a-novel-fluorescent-imaging-agent-for-medullary-thyroid-cancer-in-an-orthotopic-model
#10
Kara K Rossfeld, Steven E Justiniano, Haiming Ding, Li Gong, Shankaran Kothandaraman, Dwitiya Sawant, Motoyasu Saji, Chadwick L Wright, Lawrence S Kirschner, Matthew D Ringel, Michael F Tweedle, John E Phay
Context: The primary and definitive treatment for medullary thyroid cancer (MTC) is surgical resection. Recurrent or residual disease is typically a result of incomplete surgical removal. Objective: Our objective is to develop a compound which assists in intraoperative visualization of cancer which would have the potential to improve surgical cure rates and outcomes. Results: We report the biological characterization of Compound -17, which is labeled with IRdye800, allowing fluorescent visualization of medullary thyroid cancer mouse models...
June 7, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28585679/diagnostic-value-of-selected-biochemical-markers-in-the-detection-of-recurrence-of-medullary-thyroid-cancer-comparison-of-calcitonin-procalcitonin-chromogranin-a-and-carcinoembryonic-antigen
#11
Kosma Woliński, Jarosław Kaznowski, Aleksandra Klimowicz, Adam Maciejewski, Dagny Łapińska-Cwojdzińska, Edyta Gurgul, Adrian D Car, Marta Fichna, Paweł Gut, Maria Gryczyńska, Marek Ruchała
INTRODUCTION: Medullary thyroid cancer (MTC) is a malignancy of the thyroid gland, which derives from parafollicular C cells. Periodic measurement of biochemical markers of MTC remains a crucial part of patient follow-up and disease monitoring. The aim of the study was to compare the diagnostic value of four selected markers - calcitonin (Ct), procalcitonin (PCT), chromogranin A (CgA), and carcinoembryonic antigen (CEA). METHODS: Patients with histopathologically confirmed MTC hospitalised in a single department between January 2015 and December 2015 were included in the study...
June 6, 2017: Endokrynologia Polska
https://www.readbyqxmd.com/read/28579118/targeting-post-translational-histone-modifications-for-the-treatment-of-non-medullary-thyroid-cancer
#12
REVIEW
Marilena Celano, Catia Mio, Marialuisa Sponziello, Antonella Verrienti, Stefania Bulotta, Cosimo Durante, Giuseppe Damante, Diego Russo
Genomic and epigenetic alterations are now being exploited as molecular targets in cancer treatment. Abnormalities involving the post-translational modification of histones have been demonstrated in thyroid cancer, and they are regarded as promising molecular targets for novel drug treatment of tumors that are resistant to conventional therapies. After a brief overview of the histone modifications most commonly associated with human malignancies, we will review recently published preclinical and clinical findings regarding the use of histone-activity modulators in thyroid cancers...
June 1, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28567290/acth-secreting-medullary-thyroid-cancer-a-case-series
#13
Ayanthi A Wijewardene, Sarah J Glastras, Diana L Learoyd, Bruce G Robinson, Venessa H M Tsang
Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour that originates from the parafollicular cells of the thyroid gland. The most common presentation of MTC is with a single nodule; however, by the time of diagnosis, most have spread to the surrounding cervical lymph nodes. Cushing's syndrome is a rare complication of MTC and is due to ectopic adrenocorticotrophic hormone (ACTH) secretion by tumour cells. Cushing's syndrome presents a challenging diagnostic and management issue in patients with MTC...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28540691/expression-of-micrornas-in-thyroid-carcinoma
#14
Gaohong Zhu, Lijun Xie, Daniel Miller
MicroRNA (miRNA) are negative regulators of gene expression and subsequent protein production. This method of action translates into regulatory control over cellular processes, including development, signaling, metabolism, and apoptosis. A broad range of miRNA are shown to have abnormal expressions in thyroid cancers which could explain the pathology of tumor oncogenesis and disease progression. A review is conducted of the current research on miRNA dysregulation in thyroid cancers, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), anaplastic thyroid cancer (ATC), and medullary thyroid carcinoma (MTC)...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28506408/genetics-of-medullary-thyroid-cancer-an-overview
#15
REVIEW
Giacomo Accardo, Giovanni Conzo, Daniela Esposito, Claudio Gambardella, Marco Mazzella, Filomena Castaldo, Carlo Di Donna, Andrea Polistena, Nicola Avenia, Vittorio Colantuoni, Dario Giugliano, Daniela Pasquali
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the dominant component of the hereditary multiple endocrine neoplasia (MEN) type 2 syndromes. Three different subtypes of MEN2, such as MEN2A, MEN2B, and Familial MTC (FMTC) have been defined, based on presence or absence of hyperparathyroidism, pheocromocytoma and characteristic clinical features. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC, but there are many other mutational patterns involved...
May 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28493027/clinicopathological-characteristics-of-thyroid-cancer-in-the-federal-state-of-salzburg
#16
Gundula Rendl, Margarida Rodrigues, Gregor Schweighofer-Zwink, Josef Hutter, Anton Hittmair, Barbara Zellinger, Cornelia Hauser-Kronberger, Christian Pirich
OBJECTIVE: The aim of our investigation was to evaluate the clinicopathological characteristics and mutation patterns in newly diagnosed cases of thyroid cancer in the federal state of Salzburg, Austria, in the year 2013. METHODS: The medical records of all patients newly diagnosed with thyroid cancer in 2013 in the federal state of Salzburg were retrospectively reviewed. The clinicopathological characteristics and mutations of thyroid cancers were analyzed. RESULTS: 63 patients (mean age: 51...
May 10, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/28476040/efficacy-of-a-hsp90-inhibitor-ganetespib-in-preclinical-thyroid-cancer-models
#17
Shu-Fu Lin, Jen-Der Lin, Chuen Hsueh, Ting-Chao Chou, Chun-Nan Yeh, Ming-Huang Chen, Richard J Wong
Heat shock protein 90 is a molecular chaperon that maintains the correct folding and function of multiple client proteins. The inhibition of heat shock protein 90, which leads to the simultaneous degradation of multiple proteins involved in oncogenic signaling pathways, has revealed an innovative strategy to treat a variety of cancer types. We evaluated the therapeutic effects of ganetespib, a heat shock protein 90 inhibitor, in treating thyroid cancer. Ganetespib effectively inhibited cell proliferation in a dose-dependent manner in eight cell lines originating from four major histologic types of thyroid cancer (papillary, follicular, anaplastic and medullary)...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28471306/salvage-lenvatinib-therapy-in-metastatic-anaplastic-thyroid-cancer
#18
Nicole M Iñiguez-Ariza, Mabel M Ryder, Crystal R Hilger, Keith C Bible
BACKGROUND: Historical anaplastic thyroid cancer (ATC) outcomes have been terrible, with a median survival of only five months and <20% one-year survival. Improved outcomes are now achieved with aggressive initial therapy in stages IVA and IVB disease, but patients with distant metastatic disease (stage IVC) still do poorly; improved therapies are sorely needed. Kinase inhibitors have emerged as promising agents in the therapy of advanced medullary and differentiated thyroid cancer, but there are limited data regarding the use of lenvatinib in ATC...
May 31, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28471115/clinical-characteristics-and-treatment-of-thyroid-cancer-in-children-and-adolescents-a-retrospective-analysis-of-83-patients
#19
Xiao-Chun Mao, Wen-Qiao Yu, Jin-Biao Shang, Ke-Jing Wang
OBJECTIVE: To study the clinical characteristics, treatment, and prognosis of thyroid cancer in children and adolescents. METHODS: We performed a retrospective analysis of clinical data from 83 cases of thyroid cancer in children and adolescents from January 1990 to December 2010. We compared extra-thyroid extension, lymph node metastasis, distant metastasis, and prognosis between pediatric patients ≤12 years of age (27 cases) and those >12 years of age (56 cases)...
May 2017: Journal of Zhejiang University. Science. B
https://www.readbyqxmd.com/read/28460061/population-based-assessment-of-complications-following-surgery-for-thyroid-cancer
#20
Maria Papaleontiou, David T Hughes, Cui Guo, Mousumi Banerjee, Megan R Haymart
Context: As thyroid cancer incidence rises, more patients undergo thyroid surgery. Although post-operative complication rates have been reported in single institution studies, population-based data is limited. Objective: Determine thyroid cancer surgery complication rates and identify at-risk populations. Design/Setting/Patients: Using the Surveillance, Epidemiology, and End Results-Medicare database, we evaluated general complications within 30 days and thyroid surgery specific complications within one year in 27,912 patients who underwent surgery for differentiated or medullary thyroid cancer between 1998-2011...
April 28, 2017: Journal of Clinical Endocrinology and Metabolism
keyword
keyword
4630
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"